Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3655929 | 0.76 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL18929485 | 0.75 | P2RX7 (0.37) | P2RX7MAPK1P4HBLPLLIPG | |
| SCHEMBL19326734 | 0.73 | P2RX7 (0.38) | P2RX7MAPK1P4HBLPLLIPG | |
| SCHEMBL17449164 | 0.68 | LPL (0.32) | LPLLIPG | |
| SCHEMBL30965862 | 0.66 | P2RX7 (0.47) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL25136361 | 0.64 | MAPK1 (0.46) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL18095998 | 0.64 | P2RX7 (0.48) | P2RX7MAPK1LPLLIPG | |
| SCHEMBL15166628 | 0.63 | P2RX7 (0.34) | P2RX7MAPK1 | |
| SCHEMBL15166886 | 0.62 | P2RX7 (0.37) | P2RX7MAPK1P4HBLPLLIPG | |
| SCHEMBL2019231 | 0.62 | MAPK1 (0.53) | P2RX7MAPK1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-24 | — | — | US | disclosed |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| US-9611259-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399254-A1 | Substituted Pyridine Derivatives Useful As C-FMS Kinase Inhibitors | FLT3, ABL1, FES | P2RX7 1088/4885MAPK1 500/4885P4HB 4370/4885 |
| US-10800764-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | P2RX7 1088/4885MAPK1 500/4885P4HB 4370/4885 |
| US-11214566-B2 | Substituted pyridine derivatives useful as C-FMS kinase inhibitors | FLT3, ABL1, FES | P2RX7 1088/4885MAPK1 500/4885P4HB 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.